http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#Head http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#assertion http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#provenance http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#pubinfo http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#assertion http://purl.obolibrary.org/obo/DOID_769 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_769 http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00531 http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#association http://www.w3.org/2000/01/rdf-schema#label cyclophosphamide for injection is an alkylating drug indicated for treatment of malignant diseases 1 1 minimal change nephrotic syndrome in pediatric patients 1 2 limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established cyclophosphamide for injection is indicated for the treatment of malignant lymphomas stages iii and iv of the ann arbor staging system hodgkin s disease lymphocytic lymphoma nodular or diffuse mixed cell type lymphoma histiocytic lymphoma burkitt s lymphoma multiple myeloma leukemias chronic lymphocytic leukemia chronic granulocytic leukemia it is usually ineffective in acute blastic crisis acute myelogenous and monocytic leukemia acute lymphoblastic stem cell leukemia cyclophosphamide for injection given during remission is effective in prolonging its duration mycosis fungoides advanced disease neuroblastoma disseminated disease adenocarcinoma of the ovary retinoblastoma carcinoma of the breast cyclophosphamide for injection although effective alone in susceptible malignancies is more frequently used concurrently or sequentially with other antineoplastic drugs cyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy limitations of use the safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00531 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#provenance http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#pubinfo http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#sig http://purl.org/nanopub/x/hasSignature ICCgwSXtYbq19yshTbTueEVOdJzKXWMs6igf34XLPPHQU5b19buIaynaHKKDed44W2P8cXv31EoKCUXIKvwlic9xgBnmY1oC7gns4MbGfoiBJhj/hZXu7jyy4dw4ds3EIciXoKzImZu78Kn+5kqbjeAKhV/9uKnqJ26TFCJn9w0= http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko http://purl.org/dc/terms/created 2021-07-03T15:52:40.849+02:00 http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RASB3ewzF3iksIIg6zjr0VMVcB1Xruvp7nnjIdqW06Oko https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs